CAR-T Cell
Premium Cells
CAR T-cell Therapy
CAR T-cell therapy is a novel cancer treatment, T-cells are modified with a chimeric antigen receptor. This special molecule CAR can encourage and teach T-cells to attack cancer cells, and turn T-cells into an effective weapon against cancer. The valuable research and clinical trials led to the available treatment today. Moreover, new and better CAR-T cell therapies are being developed for cancer patients.
FDA licensed CAR T-cell therapy for adult patients with mantle cell lymphoma and aggressive B-cell lymphoma, and pediatric patients with acute lymphoblastic leukemia. Active clinical trials apply CAR T-cells for solid tumor cancers, including non-small cell lung cancer.
GMP Capacity
Advanced Manufacturing
Quality Assurance
Quality Control
Stability Analysis
Project Management
Premium Cells
Approved CAR in Lymphoma
Different CAR can target different antigens on the surface of cancer cells, The U.S. FDA has approved many CAR-T cell therapy treatments, including:
The specific antigens make CAR-T cell therapy different from other T-cell therapies like: tumor-infiltrating lymphocyte(TIL) and T-cell receptor therapies(TCR). In addition, CAR-T cell therapy also is different from stem cell transplant (SCT).
Cell Reference
Therapy Process
CAR T-cell therapy provides engineered molecules(chimeric antigen receptors, CARs) to recognize and destroy antigens on the surface of lymphoma cells. Genetic engineering CAR T-cells are grown in the laboratory to billions number, then infused back into the cancer patient.
CAR T-cell Process
Cell Application
Cancer Treatment
CAR T-cell therapy is applied for cancer treatment like leukemian, lymphoma, multiple myeloma. It is also approved to treat recurrences of the following cancers:
